Stock Traders Buy Large Volume of CorMedix Call Options (NASDAQ:CRMD)

CorMedix Inc (NASDAQ:CRMD) was the recipient of unusually large options trading on Thursday. Stock investors acquired 2,471 call options on the stock. This is an increase of 42% compared to the average volume of 1,736 call options.

CorMedix News Roundup

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: CorMedix beat Q1 estimates, with DefenCath driving triple-digit revenue growth and supporting a higher full-year outlook. CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
• Positive Sentiment: The company raised FY2026 revenue guidance to $325 million-$345 million, above Wall Street expectations, signaling management confidence in continued demand and execution. CorMedix Q1 2026 Financial Results and Business Update
• Positive Sentiment: CorMedix announced upcoming investor conference participation, which could help keep attention on the name and provide more updates on growth strategy. CorMedix to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst commentary and earnings-call recaps are reinforcing the same message: strong quarterly performance, improving profitability, and continued momentum in the core product. Analysts Offer Insights on Healthcare Companies: Immatics and CorMedix
• Neutral Sentiment: Unusually heavy options activity suggests traders expect continued volatility around the earnings-driven move in CRMD.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CRMD. Financial Management Professionals Inc. bought a new stake in shares of CorMedix during the 4th quarter worth $25,000. Comerica Bank raised its position in shares of CorMedix by 454.6% during the third quarter. Comerica Bank now owns 2,690 shares of the company’s stock worth $31,000 after purchasing an additional 2,205 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of CorMedix during the second quarter valued at $42,000. Kestra Advisory Services LLC purchased a new stake in shares of CorMedix during the fourth quarter valued at $49,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of CorMedix by 666.6% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company’s stock valued at $51,000 after purchasing an additional 3,813 shares during the period. Institutional investors own 34.18% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. HC Wainwright lowered their price target on shares of CorMedix from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. D. Boral Capital reissued a “buy” rating and set a $14.00 target price on shares of CorMedix in a research note on Monday, April 27th. Weiss Ratings upgraded shares of CorMedix from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday. Zacks Research lowered shares of CorMedix from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 10th. Finally, Needham & Company LLC lifted their price target on CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, April 27th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CorMedix presently has a consensus rating of “Moderate Buy” and an average target price of $15.00.

CorMedix Price Performance

CorMedix stock traded down $0.38 during trading hours on Friday, hitting $7.55. 2,835,008 shares of the company traded hands, compared to its average volume of 1,165,390. CorMedix has a 1-year low of $6.13 and a 1-year high of $17.43. The firm has a market cap of $592.24 million, a P/E ratio of 3.54 and a beta of 1.46. The firm’s 50-day simple moving average is $7.10 and its two-hundred day simple moving average is $8.66. The company has a quick ratio of 1.94, a current ratio of 2.11 and a debt-to-equity ratio of 0.36.

CorMedix (NASDAQ:CRMD) last released its earnings results on Thursday, May 14th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.35 by $0.08. CorMedix had a return on equity of 49.12% and a net margin of 45.25%.The firm had revenue of $127.43 million during the quarter, compared to the consensus estimate of $104.96 million. During the same period in the prior year, the firm posted $0.30 earnings per share. The firm’s revenue for the quarter was up 226.1% compared to the same quarter last year. As a group, analysts forecast that CorMedix will post 0.44 earnings per share for the current fiscal year.

CorMedix declared that its Board of Directors has initiated a stock buyback program on Monday, February 2nd that allows the company to repurchase $75.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 12.3% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

About CorMedix

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.